Every material Form 8-K Inhibrx Biosciences, Inc. has filed with the SEC since August 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Inhibrx Biosciences posted an updated corporate presentation to its website on September 28, 2026, and filed it as Exhibit 99.1 to this 8-K. The presentation shows early Phase 2 HexAgon-HN data for INBRX-106 combined with pembrolizumab, and it says a planned 50-patient expansion of the HPV-positive cohort may support a potential accelerated approval path by the end of 2028 or early 2029. The filing reports no new financial results, and the company states it has no obligation to update the materials.
HPV-positive cohort: confirmed objective response rate of 80.0% (8 of 10) with INBRX-106 plus pembrolizumab, versus 33.3% (3 of 9) with pembrolizumab alone, per the presentation.
Overall randomized population: objective response rate of 48.3% versus 26.5%, with a primary endpoint of cORR per the presentation; data cutoff August 19, 2026.
The company says it had $219.5 million in cash and cash equivalents and 14.7 million common shares outstanding as of August 6, 2026.
The presentation says the study amendment adds 50 HPV-positive patients, with potential accelerated approval by end of 2028 or early 2029.
Inhibrx Biosciences reported primary endpoint results from the randomized Phase 2 portion of its HexAgon study of INBRX-106 plus pembrolizumab in first-line head and neck squamous cell carcinoma, with a data cutoff of August 19, 2026. The company plans to add about 50 HPV+ oropharyngeal patients to the Phase 2 portion to support a potential accelerated regulatory pathway, then align with the FDA and start a Phase 3 confirmatory portion.
Confirmed objective response rate was 48.3% for INBRX-106 plus pembrolizumab vs 26.5% for pembrolizumab alone; 4 patients (13.8%) in the combination arm had a complete response vs none in the control arm.
Median progression-free survival was 9.6 months vs 4.9 months, though the company said median PFS continues to mature.
In HPV+ patients, confirmed objective response rate was 80.0% vs 33.3%, based on 10 combination-arm and 9 control-arm patients.
The most common treatment-related adverse events were rash, fatigue and diarrhea, which the company described as predominantly low grade.
Inhibrx reported second-quarter 2026 results showing a net loss of $36.7 million, or $2.34 per share, compared with $28.7 million, or $1.85 per share, a year earlier. The company recognized no revenue in the quarter, down from $1.3 million in the second quarter of 2025, and higher interest expense on its loan contributed to the larger loss.
Net loss of $36.7 million ($2.34 per share) vs. $28.7 million ($1.85 per share) in Q2 2025
No revenue in Q2 2026 vs. $1.3 million in Q2 2025 from the Scithera license transfer
R&D expense rose to $23.9 million from $22.3 million; G&A rose to $8.3 million from $6.4 million
Cash was $133.3 million at June 30, 2026, and $219.5 million as of August 6, 2026, after $100.0 million was funded under the Oxford loan amendment on July 15, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Inhibrx Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →